Skip to main content Skip to choc.org search

TINI, Total Therapy For Infants with Acute Lymphoblastic Leukemia (ALL) I

The purpose of this study is to test the good and bad effects of the study drugs bortezomib and vorinostat when they are given in combination with chemotherapy commonly used to treat acute lymphoblastic leukemia (ALL) in infants. For example, adding these drugs could decrease the number of leukemia cells, but it could also cause additional side effects. Bortezomib and vorinostat have been approved by the US Food and Drug Administration (FDA) to treat other cancers in adults, but they have not been approved for treating children with leukemia.

Principal Investigator:
Ivan Kirov, MD

Research Coordinator:
Dorian Chan
(714) 509-8646

Visit clinicaltrials.gov for more information about this trial.



  • Clinical Trial Info
  • IRB Number: 1611111
  • Sponsor: St. Jude Children's Research Hospital
  • Protocol Number: TINI
  • NCT Number: NCT02553460
  • Research Type: Leukemia
  • Phase: III
  • Status: Active - Open to Enrollment

Long Live Childhood

Facebook Twitter Pinterest Instagram Snapchat LinkedIn YouTube